Affyimmune Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://affyimmune.com
Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
Phase 1
Active, not recruiting
- Conditions
- Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
- Interventions
- Biological: AIC100 CAR T Cells
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- AffyImmune Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04420754
- Locations
- 🇺🇸
City of Hope National Medical Center, City of Hope Medical Center, Duarte, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
News
No news found